In adult patients with recurrent Clostridium difficile infection, Fecal microbiota transplantation (FMT) performed better than Vancomycin alone or Fidaxomicin alone.
in this open-labeled randomized trial published in the journal Gastroenterology, Hvas et al randomized 64 adults in one of the following three groups:
1- FMT by colonoscopy or nasojejunal tube, after 4–10 days of vancomycin (125 mg 4 times daily),
2- Fidaxomicin 200 mg twice daily for 10 days
3- Vancomycin 125 mg 4 times daily for 10 days.
The primary outcome was combined clinical resolution and a negative result from a polymerase chain reaction test for Clostridium difficile toxin 8 weeks after the treatment.
The primary outcome was met in 71% of FMT group, 33% in the Vancomycin group and 19% in Fidaxomicin group.
The future is bright for fecal transplantation in Clostridium difficile infection
Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection
Christian Lodberg Hvas,1 Simon Mark Dahl Jørgensen,1 Søren Peter Jørgensen,1 Merete Storgaard,2 Lars Lemming,3 Mette Mejlby Hansen,1 Christian Erikstrup,4 and Jens Frederik Dahlerup1
1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; 2 Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; 3 Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark; and 4 Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark